Cargando…

Management of Fibrosis: The Mesenchymal Stromal Cells Breakthrough

Fibrosis is the endpoint of many chronic inflammatory diseases and is defined by an abnormal accumulation of extracellular matrix components. Despite its slow progression, it leads to organ malfunction. Fibrosis can affect almost any tissue. Due to its high frequency, in particular in the heart, lun...

Descripción completa

Detalles Bibliográficos
Autores principales: Usunier, Benoît, Benderitter, Marc, Tamarat, Radia, Chapel, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123563/
https://www.ncbi.nlm.nih.gov/pubmed/25132856
http://dx.doi.org/10.1155/2014/340257
_version_ 1782329509122408448
author Usunier, Benoît
Benderitter, Marc
Tamarat, Radia
Chapel, Alain
author_facet Usunier, Benoît
Benderitter, Marc
Tamarat, Radia
Chapel, Alain
author_sort Usunier, Benoît
collection PubMed
description Fibrosis is the endpoint of many chronic inflammatory diseases and is defined by an abnormal accumulation of extracellular matrix components. Despite its slow progression, it leads to organ malfunction. Fibrosis can affect almost any tissue. Due to its high frequency, in particular in the heart, lungs, liver, and kidneys, many studies have been conducted to find satisfactory treatments. Despite these efforts, current fibrosis management therapies either are insufficiently effective or induce severe adverse effects. In the light of these facts, innovative experimental therapies are being investigated. Among these, cell therapy is regarded as one of the best candidates. In particular, mesenchymal stromal cells (MSCs) have great potential in the treatment of inflammatory diseases. The value of their immunomodulatory effects and their ability to act on profibrotic factors such as oxidative stress, hypoxia, and the transforming growth factor-β1 pathway has already been highlighted in preclinical and clinical studies. Furthermore, their propensity to act depending on the microenvironment surrounding them enhances their curative properties. In this paper, we review a large range of studies addressing the use of MSCs in the treatment of fibrotic diseases. The results reported here suggest that MSCs have antifibrotic potential for several organs.
format Online
Article
Text
id pubmed-4123563
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-41235632014-08-17 Management of Fibrosis: The Mesenchymal Stromal Cells Breakthrough Usunier, Benoît Benderitter, Marc Tamarat, Radia Chapel, Alain Stem Cells Int Review Article Fibrosis is the endpoint of many chronic inflammatory diseases and is defined by an abnormal accumulation of extracellular matrix components. Despite its slow progression, it leads to organ malfunction. Fibrosis can affect almost any tissue. Due to its high frequency, in particular in the heart, lungs, liver, and kidneys, many studies have been conducted to find satisfactory treatments. Despite these efforts, current fibrosis management therapies either are insufficiently effective or induce severe adverse effects. In the light of these facts, innovative experimental therapies are being investigated. Among these, cell therapy is regarded as one of the best candidates. In particular, mesenchymal stromal cells (MSCs) have great potential in the treatment of inflammatory diseases. The value of their immunomodulatory effects and their ability to act on profibrotic factors such as oxidative stress, hypoxia, and the transforming growth factor-β1 pathway has already been highlighted in preclinical and clinical studies. Furthermore, their propensity to act depending on the microenvironment surrounding them enhances their curative properties. In this paper, we review a large range of studies addressing the use of MSCs in the treatment of fibrotic diseases. The results reported here suggest that MSCs have antifibrotic potential for several organs. Hindawi Publishing Corporation 2014 2014-07-14 /pmc/articles/PMC4123563/ /pubmed/25132856 http://dx.doi.org/10.1155/2014/340257 Text en Copyright © 2014 Benoît Usunier et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Usunier, Benoît
Benderitter, Marc
Tamarat, Radia
Chapel, Alain
Management of Fibrosis: The Mesenchymal Stromal Cells Breakthrough
title Management of Fibrosis: The Mesenchymal Stromal Cells Breakthrough
title_full Management of Fibrosis: The Mesenchymal Stromal Cells Breakthrough
title_fullStr Management of Fibrosis: The Mesenchymal Stromal Cells Breakthrough
title_full_unstemmed Management of Fibrosis: The Mesenchymal Stromal Cells Breakthrough
title_short Management of Fibrosis: The Mesenchymal Stromal Cells Breakthrough
title_sort management of fibrosis: the mesenchymal stromal cells breakthrough
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123563/
https://www.ncbi.nlm.nih.gov/pubmed/25132856
http://dx.doi.org/10.1155/2014/340257
work_keys_str_mv AT usunierbenoit managementoffibrosisthemesenchymalstromalcellsbreakthrough
AT benderittermarc managementoffibrosisthemesenchymalstromalcellsbreakthrough
AT tamaratradia managementoffibrosisthemesenchymalstromalcellsbreakthrough
AT chapelalain managementoffibrosisthemesenchymalstromalcellsbreakthrough